BioSpace News Archive

Drug Development

Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting

Xencor, Inc. today announced initial data from its ongoing Phase 1 dose-escalation study of XmAb®14045, a CD123 x CD3 bispecific antibody, in patients with relapsed/refractory acute myeloid leukemia (AML).

December 3, 2018
·
6 min read
Drug Development

Ascentage Pharma Announces Oral Presentation of Novel, Third-Generation BCR-ABL Inhibitor in Myelogenous Leukemia Patients at the 60th American Society of Hematology Annual Meeting

Ascentage Pharma today announced data from a Phase 1 clinical study of its novel BCR-ABL inhibitor, HQP1351, in patients with Tyrosine Kinase Inhibitor (TKI)-refractory chronic myelogenous leukemia (CML) at the 60th American Society of Hematology (ASH) Annual Meeting.

December 3, 2018
·
3 min read
Policy

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of United Therapeutics Corporation - UTHR

Pomerantz LLP is investigating claims on behalf of investors of United Therapeutics Corporation (“United Therapeutics” or the “Company”) (NASDAQ: UTHR).

December 3, 2018
·
1 min read
Biotech Beach

When Good Macrophages Go Bad: New Study Reveals How Cancer Manipulates Our Immune System to Become Harder to Treat

Many factors affect cancer treatment outcome, such as the size and location of the tumor, availability of effective treatments, and timing of intervention.

December 3, 2018
·
4 min read
Biotech Bay

GRAIL Announces Plans to Initiate SUMMIT Study to Support Development of Blood Test for Early Cancer Detection

SUMMIT Study Partners Include UCL and University College London Hospitals NHS Foundation Trust in the United Kingdom, and Lung Cancer Alliance

December 3, 2018
·
5 min read
Drug Development

Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson reported today updated results from Legend Biotech Inc.'s LEGEND-2 Phase 1/2 open-label study, which evaluated the investigational chimeric antigen receptor T-cell (CAR-T) therapy LCAR-B38M in the treatment of patients with advanced relapsed or refractory (R/R) multiple myeloma.

December 3, 2018
·
9 min read
Drug Development

Celgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 Evolve Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018

82% overall response rate observed in heavily pre-treated patients

December 3, 2018
·
3 min read
Drug Development

Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Ongoing Phase 1/2 Study Continues to Demonstrate High Rates of Response to a Single Infusion of KTE-X19 in a Patient Population with Limited Treatment Options

December 3, 2018
·
5 min read
Drug Development

Results Presented from Primary Analysis of the Phase III HAVEN 2 Study with Chugai’s HEMLIBRA® for Children with Hemophilia A with Inhibitors at the American Society of Hematology 2018

Chugai Pharmaceutical Co., Ltd. announced that the primary analysis of the phase III HAVEN 2 study (NCT02795767), evaluating hemophilia A treatment HEMLIBRA® in children with hemophilia A with factor VIII inhibitors, was reported in an Oral Presentation at the 60th American Society of Hematology (ASH) Annual Meeting held in San Diego, USA from December 1 to 4 2018.

December 3, 2018
·
6 min read
Drug Development

bluebird bio Presents New Data for LentiGlobin Gene Therapy in Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology

LentiGlobin treatment-derived hemoglobin HbAT87Q equals or exceeds sickling hemoglobin (HbS) levels in Group C patients at six months post treatment

December 3, 2018
·
8 min read